The Biggest Bottlenecks Holding Back Cell and Gene Therapy
August 24, 2026
Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges
9 min read
False
Advertisement
Development & Clinical
Musings from The Power List: Daniel Vitt
By Daniel Vitt
August 20, 2026
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
6 min read
The Road to Commercial-Scale iPSC Cell Therapy
August 19, 2026
Can iPSC platforms deliver consistent, commercial-scale cell therapies for large patient populations?
5 min read
The Mindset for Success in Biopharma's New Multipolar World
By Jessica Allerton, James Strachan
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
Musings from The Power List: John Maher
By John Maher
August 14, 2026
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
4 min read
Development & Clinical
Regulation & Standards
Business & Trends
Technology & Manufacturing
Sponsored
From Training Burden to Training Value
August 14, 2026
Why effective study training depends on relevance, timing, and oversight.
0 min read
Why Cell Therapy Needs a Digital Backbone
August 13, 2026
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
8 min read
What Did ASCO 2026 Reveal About the Future of Oncology?
By James Strachan
August 6, 2026
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
8 min read
How China Is Rewriting the Rules Global Drug Development
By James Strachan
August 5, 2026
In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development
14 min read
The 10 Biggest Bottlenecks Slowing Drug Development
August 4, 2026
Ten industry leaders from the 2026 Power List identify the scientific, clinical, regulatory, and financial barriers holding drug development back
6 min read
